Analytical Data
-
Gene name
CHRNb4
- Application
-
Alternative Names
CHR-NB4; CHRN-B4; N-AChRB4; NAChRB4; N-AChR-B4; Neuronal Acetylcholine Receptor Beta 4
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30926
-
Expression Region
Arg22~Thr236
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHRNb4, or the nicotinic acetylcholine receptor subunit beta-4, has garnered significant attention in recent years due to its pivotal role in neurotransmission and its involvement in various neurological disorders. This receptor subunit is a component of heteromeric nicotinic receptors, which are crucial for mediating cholinergic signaling in both the central and peripheral nervous systems. Research has indicated that CHRNb4 plays a critical role in modulating synaptic plasticity, attention, and learning processes, making it a subject of interest in the context of cognitive function and neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, polymorphisms in the CHRNb4 gene have been associated with susceptibility to nicotine addiction and other psychiatric conditions. The study of recombinant CHRNb4 protein aims to elucidate its structure, function, and interactions with other receptor subunits, providing insights into its physiological roles and potential as a therapeutic target. As such, the recombinant protein research facilitates the understanding of ion channel dynamics, pharmacological profiles, and the design of novel compounds that can selectively modulate CHRNb4 activity, offering promising avenues for treatment strategies in disorders linked to cholinergic dysfunction. By advancing our grasp of CHRNb4’s mechanistic pathways, researchers hope to unravel the complexities of cholinergic signaling and its implications in health and disease.
